Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
Abstract Coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits high levels of mortality and morbidity and has dramatic consequences on human life, sociality and global economy. Neutralizing antibodies constitute a highly promising approach for treating and preventing infection by this novel pathogen. In the present study, we characterized and further evaluated the recently identified human monoclonal MD65 antibody for its ability to provide protection against a lethal SARS-CoV-2 infection of K18-hACE2 transgenic mice. Eighty percent of the untreated mice succumbed 6-9 days post-infection while administration of the MD65 antibody as late as 3 days after exposure, rescued all infected animals. In addition, the efficiency of the treatment is supported by prevention of morbidity and ablation of the load of infective virions in the lungs of treated animals. The data unprecedentedly demonstrate, the therapeutic value of human monoclonal antibodies as a life-saving treatment of severe COVID-19 infection..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 15. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rosenfeld, Ronit [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.10.26.354811 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019216041 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019216041 | ||
| 003 | DE-627 | ||
| 005 | 20230429084922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201028s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.10.26.354811 |2 doi | |
| 035 | |a (DE-627)XBI019216041 | ||
| 035 | |a (biorXiv)10.1101/2020.10.26.354811 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Rosenfeld, Ronit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits high levels of mortality and morbidity and has dramatic consequences on human life, sociality and global economy. Neutralizing antibodies constitute a highly promising approach for treating and preventing infection by this novel pathogen. In the present study, we characterized and further evaluated the recently identified human monoclonal MD65 antibody for its ability to provide protection against a lethal SARS-CoV-2 infection of K18-hACE2 transgenic mice. Eighty percent of the untreated mice succumbed 6-9 days post-infection while administration of the MD65 antibody as late as 3 days after exposure, rescued all infected animals. In addition, the efficiency of the treatment is supported by prevention of morbidity and ablation of the load of infective virions in the lungs of treated animals. The data unprecedentedly demonstrate, the therapeutic value of human monoclonal antibodies as a life-saving treatment of severe COVID-19 infection. | ||
| 700 | 1 | |a Noy-Porat, Tal |e verfasserin |4 aut | |
| 700 | 1 | |a Mechaly, Adva |e verfasserin |4 aut | |
| 700 | 1 | |a Makdasi, Efi |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Yinon |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalay, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Falach, Reut |e verfasserin |4 aut | |
| 700 | 1 | |a Aftalion, Moshe |e verfasserin |4 aut | |
| 700 | 1 | |a Epstein, Eyal |e verfasserin |4 aut | |
| 700 | 1 | |a Gur, David |e verfasserin |4 aut | |
| 700 | 1 | |a Chitlaru, Theodor |e verfasserin |4 aut | |
| 700 | 1 | |a Vitner, Einat B. |e verfasserin |4 aut | |
| 700 | 1 | |a Melamed, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Politi, Boaz |e verfasserin |4 aut | |
| 700 | 1 | |a Zauberman, Ayelet |e verfasserin |4 aut | |
| 700 | 1 | |a Lazar, Shirley |e verfasserin |4 aut | |
| 700 | 1 | |a Beth-Din, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Evgy, Yentl |e verfasserin |4 aut | |
| 700 | 1 | |a Yitzhaki, Shmuel |e verfasserin |4 aut | |
| 700 | 1 | |a Shapira, Shmuel C. |e verfasserin |4 aut | |
| 700 | 1 | |a Israely, Tomer |e verfasserin |4 aut | |
| 700 | 1 | |a Mazor, Ohad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-021-21239-8 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.10.26.354811 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 15 |c 12 | ||
| 953 | |2 045F |a 570 | ||